Veit Sandfort1, David A Bluemke, Jose Vargas, Jeffrey A Brinker, Gary Gerstenblith, Thomas Kickler, Gang Zheng, Ji Li, Shaoguang Chen, Hong Lai, Elliot K Fishman, Shenghan Lai. 1. Department of Radiology and Imaging Sciences (VS, DAB, JV), National Institutes of Health Clinical, Center, Bethesda; Department of Radiology (DAB, HL, EKF, SL), Johns Hopkins School of Medicine, Baltimore, MD; MedStar Health Research Institute (JV), Georgetown University Hospital, Washington, DC; Department of Medicine (JAB, GG, SL); and Department of Pathology (TK, GZ, JL, SC, SL), Johns Hopkins School of Medicine, Baltimore, MD.
Abstract
OBJECTIVE: Although rapid progression of coronary atherosclerosis was observed in chronic cocaine users, it is unknown whether reduced cocaine use retards the progression of atherosclerosis. We investigated whether reduced cocaine use over a 12-month period was associated with coronary plaque regression in cocaine users. METHODS: Fifteen African American chronic cocaine users with previously coronary computed tomography angiography (CCTA)-confirmed >50% coronary stenosis in Baltimore, Maryland, were enrolled in a study to investigate whether reduced cocaine use is associated with changes in coronary plaque burden over a 12-month period of cash-based incentive intervention, which was implemented to systematically reinforce cocaine abstinence. In addition to previous CCTA (preintervention), CCTA was performed at the intervention baseline and at postintervention. Plaque analyses were performed to determine the trajectory of plaque changes in the absence of intervention by comparing the preintervention with the intervention baseline studies; the trajectory of plaque changes associated with the intervention by comparing the intervention baseline with the postintervention studies; and (3) whether reduced cocaine use was independently associated with changes in coronary plaque burden. RESULTS: During the 12-month cash-based incentive intervention period, cocaine use in participants was lower. The medians of noncalcified plaque indices were 37.8 (interquartile range [IQR] 29.3-44.0), 43.1 (IQR 38.3-49.0), and 38.7 (IQR 31.2-46.8) mm at preintervention, intervention baseline, and postintervention, respectively. Multivariable generalized estimating equation analysis showed that both total plaque and noncalcified plaque indices at preintervention were significantly lowered as compared with intervention baseline levels; both total plaque and noncalcified plaque indices after intervention were significantly lowered as compared with intervention baseline levels; and reduced cocaine use was independently associated with lower total plaque volume index (P < 0.0001) and noncalcified plaque volume index (P = 0.010). CONCLUSIONS: Our findings suggest that continued cocaine use may be associated with noncalcified plaque progression, whereas reduced cocaine use may be associated with noncalcified plaque regression. Larger studies are needed to confirm these findings.
OBJECTIVE: Although rapid progression of coronary atherosclerosis was observed in chronic cocaine users, it is unknown whether reduced cocaine use retards the progression of atherosclerosis. We investigated whether reduced cocaine use over a 12-month period was associated with coronary plaque regression in cocaine users. METHODS: Fifteen African American chronic cocaine users with previously coronary computed tomography angiography (CCTA)-confirmed >50% coronary stenosis in Baltimore, Maryland, were enrolled in a study to investigate whether reduced cocaine use is associated with changes in coronary plaque burden over a 12-month period of cash-based incentive intervention, which was implemented to systematically reinforce cocaine abstinence. In addition to previous CCTA (preintervention), CCTA was performed at the intervention baseline and at postintervention. Plaque analyses were performed to determine the trajectory of plaque changes in the absence of intervention by comparing the preintervention with the intervention baseline studies; the trajectory of plaque changes associated with the intervention by comparing the intervention baseline with the postintervention studies; and (3) whether reduced cocaine use was independently associated with changes in coronary plaque burden. RESULTS: During the 12-month cash-based incentive intervention period, cocaine use in participants was lower. The medians of noncalcified plaque indices were 37.8 (interquartile range [IQR] 29.3-44.0), 43.1 (IQR 38.3-49.0), and 38.7 (IQR 31.2-46.8) mm at preintervention, intervention baseline, and postintervention, respectively. Multivariable generalized estimating equation analysis showed that both total plaque and noncalcified plaque indices at preintervention were significantly lowered as compared with intervention baseline levels; both total plaque and noncalcified plaque indices after intervention were significantly lowered as compared with intervention baseline levels; and reduced cocaine use was independently associated with lower total plaque volume index (P < 0.0001) and noncalcified plaque volume index (P = 0.010). CONCLUSIONS: Our findings suggest that continued cocaine use may be associated with noncalcified plaque progression, whereas reduced cocaine use may be associated with noncalcified plaque regression. Larger studies are needed to confirm these findings.
Authors: Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani Journal: Circulation Date: 2002-01-29 Impact factor: 29.690
Authors: Edward A Hulten; Salvatore Carbonaro; Sara P Petrillo; Joshua D Mitchell; Todd C Villines Journal: J Am Coll Cardiol Date: 2010-12-08 Impact factor: 24.094
Authors: Anna Marie Chang; Kristy M Walsh; Frances S Shofer; Christine M McCusker; Harold I Litt; Judd E Hollander Journal: Acad Emerg Med Date: 2010-12-23 Impact factor: 3.451
Authors: Matthias Bossard; Katrin Pumpol; Stéphanie van der Lely; Stefanie Aeschbacher; Tobias Schoen; Philipp Krisai; Tschuenschen Lam; John Todd; Joel Estis; Martin Risch; Lorenz Risch; David Conen Journal: Atherosclerosis Date: 2015-01-14 Impact factor: 5.162
Authors: Maros Ferencik; Thomas Mayrhofer; Stefan B Puchner; Michael T Lu; Pal Maurovich-Horvat; Ting Liu; Khristine Ghemigian; Pieter Kitslaar; Alexander Broersen; Fabian Bamberg; Quynh A Truong; Christopher L Schlett; Udo Hoffmann Journal: J Cardiovasc Comput Tomogr Date: 2015-07-10
Authors: Shenghan Lai; Elliot K Fishman; Hong Lai; Richard Moore; Joseph Cofrancesco; Harpreet Pannu; Wenjing Tong; Jiefu Du; John Barlett Journal: Clin Infect Dis Date: 2008-02-15 Impact factor: 9.079
Authors: Doris Hsinyu Chen; Márton Kolossváry; Shaoguang Chen; Hong Lai; Hsin-Chieh Yeh; Shenghan Lai Journal: Am J Drug Alcohol Abuse Date: 2020-09-29 Impact factor: 3.829
Authors: Maria Luisa Alcaide; Violeta J Rodriguez; John M Abbamonte; Suresh Pallikuth; Jake Langlie; Manasi Soni; Stephen M Weiss; Barry E Hurwitz; Savita Pahwa; Deborah L Jones; Mahendra Kumar Journal: AIDS Care Date: 2019-09-23
Authors: Shenghan Lai; Christopher M Heaphy; Anthony J Rizzo; David D Celentano; Gary Gerstenblith; Ji Li; Richard D Moore; Glenn Treisman; Shaoguang Chen; Parker Foster; Thomas Kickler; Hong Lai Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2018-02-02 Impact factor: 5.067
Authors: Parker Foster; Lori Sokoll; Ji Li; Gary Gerstenblith; Elliot K Fishman; Thomas Kickler; Shaoguang Chen; Hong Tai; Hong Lai; Shenghan Lai Journal: Int J STD AIDS Date: 2018-10-31 Impact factor: 1.359
Authors: Qing Cao; Alexander Broersen; Pieter H Kitslaar; Mingyuan Yuan; Boudewijn P F Lelieveldt; Jouke Dijkstra Journal: Med Phys Date: 2020-01-20 Impact factor: 4.071